Three Gujarat Dermatologists Suspended for 13 Months Over Sponsored Trip

New Delhi, India Jul 1, 2026 ALN: Ahmedabad: The Gujarat Medical Council (GMC) has suspended the registrations of three dermatologists from the state for 13 months over alleged professional misconduct linked to an industry-sponsored foreign trip. This decision marks a significant moment in the ongoing discourse surrounding the ethics of medical professionals in India, particularly regarding their relationships with pharmaceutical companies.

The doctors involved in this case, Dr. Jagdishkumar Sakhiya and Dr. Ami Shah from Surat, along with Dr. Geeta Patel from Ahmedabad, were among a group of 30 medical professionals from nine different states who attended international conferences in Paris and Monaco in 2024. Reports indicate that their travel and hospitality expenses were allegedly covered by AbbVie Healthcare India Pvt Ltd., a prominent biotech firm. Such sponsorships have raised ethical concerns in the medical community, as they may influence clinical practices and treatment recommendations.

The scrutiny into this matter intensified after the National Medical Commission (NMC) uncovered that doctors from various states, including Gujarat, Maharashtra, Telangana, Punjab, Karnataka, West Bengal, Delhi, Assam, and Kerala, had allegedly accepted travel and hospitality benefits exceeding Rs. 1 lakh per participant from the pharmaceutical company. This revelation has sparked a broader discussion about the potential conflicts of interest that arise when healthcare professionals accept gifts or sponsorships from pharmaceutical companies.

In its order dated June 30, the GMC stated that accepting such benefits constituted a breach of Clause 6.8 of the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002. This clause explicitly prohibits medical practitioners from accepting any kind of material benefit from pharmaceutical companies that could compromise their professional judgment. The GMC's decision was informed by the provisions outlined in the Uniform Code of Pharmaceutical Marketing Practices (2014 and 2024), as well as the ethical regulations established in 2002. In addition, the council considered resolutions passed by both the GMC’s general body and executive committee, reflecting a consensus on the need for strict adherence to ethical standards within the medical community.

The actions taken against the three dermatologists are notable as they highlight the GMC's commitment to enforcing ethical standards among medical practitioners. Sources indicate that the doctors were issued show-cause notices and given ample opportunity to present their case. They submitted their responses and supporting documents on January 8 and June 29, respectively, prior to the final order being issued. This procedural fairness underscores the GMC's approach to ensuring that due process is followed in disciplinary matters.

As a result of the suspension, the three doctors will be prohibited from practicing medicine in Gujarat or exercising any rights or privileges associated with their medical registration for the duration of the 13-month period. The GMC has indicated that their registrations may be restored after the suspension ends, contingent upon compliance with the relevant legal and regulatory provisions.

This case is part of a broader trend in India where regulatory bodies are increasingly scrutinizing the relationships between healthcare professionals and the pharmaceutical industry. The growing awareness of ethical practices in medicine has led to calls for greater transparency and accountability among medical practitioners. The acceptance of gifts, sponsorships, and other benefits from pharmaceutical companies has been a contentious issue, with critics arguing that such practices can lead to biased medical advice and compromised patient care.

The implications of this suspension extend beyond the individual doctors involved. It serves as a warning to other medical professionals about the potential consequences of accepting industry-sponsored benefits. The GMC's decision may encourage other state medical councils to adopt similar measures, reinforcing the importance of ethical conduct in the medical profession.

Furthermore, this incident could lead to increased public scrutiny of the medical profession, as patients and families become more aware of the potential conflicts of interest that may arise from industry sponsorship. As healthcare consumers seek greater transparency in the medical field, doctors may find themselves under pressure to disclose any relationships with pharmaceutical companies and to justify their treatment decisions.

In light of these developments, it is crucial for medical professionals to engage in ongoing education about the ethical implications of their relationships with the pharmaceutical industry. Many medical institutions are now incorporating training on ethics and professionalism into their curricula, aiming to equip future healthcare providers with the tools necessary to navigate these complex issues.

As the medical community continues to grapple with these ethical dilemmas, the GMC's actions could serve as a catalyst for change. By holding practitioners accountable for their conduct, regulatory bodies can help foster a culture of integrity and trust within the healthcare system. Ultimately, the goal is to ensure that patient welfare remains the top priority, free from the influence of external commercial interests.

This case also raises questions about the effectiveness of existing regulations governing the interactions between medical professionals and the pharmaceutical industry. While the Indian Medical Council's regulations provide a framework for ethical conduct, ongoing discussions among stakeholders may lead to calls for more robust policies and enforcement mechanisms to prevent similar incidents in the future.

In conclusion, the suspension of these three dermatologists serves as a pivotal moment in the ongoing dialogue about ethics in medicine. As the healthcare landscape evolves, it is essential for medical professionals to prioritize ethical standards and maintain the trust of the public they serve. The GMC's decision not only addresses the specific actions of the involved doctors but also reinforces the broader commitment to maintaining integrity within the medical profession in India.